Study demonstrates ability of entolimod to suppress liver metastases
A study published in December 16, 2015, in Oncotarget demonstrated the ability of entolimod to suppress liver metastases in a preclinical model of uveal melanoma (UM). The study was led by Hans Grossniklaus and Lyudmila Burdelya, PhD, Assistant Professor of Oncology in the Department of Cell Stress Biology at Roswell Park Cancer Institute (RPCI).
Uveal melanoma is the most common primary cancer of the eye in adults, with 2,000-2,500 new diagnoses per year in the United States. Primary UM tumors are usually treated with surgery, radiation therapy and/or thermotherapy. Despite these treatments, about 50% of all UM cases progress to metastatic disease. Most metastasis of UM (80-90%) occurs in the liver, and UM patients with a “class 2” gene expression signature have an extremely poor survival prognosis due to development of detectable metastases in the liver within three years of primary tumor diagnosis.
There are currently no effective treatments for metastatic UM, and there is an average life expectancy of nine months from the time of detection of metastases.Press release